Pharvaris (NASDAQ:PHVS) Price Target Raised to $79.00 at Citizens Jmp

Pharvaris (NASDAQ:PHVS) had its target price raised by investment analysts at Citizens Jmp from $75.00 to $79.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. Citizens Jmp’s price objective would indicate a potential upside of 108.77% from the company’s current price.

Other equities research analysts have also recently issued reports about the company. Wedbush reiterated an “outperform” rating and issued a $42.00 price target on shares of Pharvaris in a research note on Tuesday. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Pharvaris in a report on Tuesday. Citigroup reissued a “market outperform” rating on shares of Pharvaris in a research note on Wednesday. Oppenheimer restated an “outperform” rating and set a $75.00 target price on shares of Pharvaris in a research report on Tuesday. Finally, HSBC raised Pharvaris to an “overweight” rating in a research note on Thursday, August 13th. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Pharvaris presently has an average rating of “Moderate Buy” and a consensus target price of $54.46.

Pharvaris Trading Up 7.3%

NASDAQ PHVS opened at $37.84 on Wednesday. Pharvaris has a 12 month low of $20.65 and a 12 month high of $43.25. The company has a market capitalization of $2.48 billion, a PE ratio of -12.41 and a beta of -2.33. The stock has a 50-day simple moving average of $34.86 and a 200 day simple moving average of $31.20.

Pharvaris (NASDAQ:PHVS) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). As a group, sell-side analysts predict that Pharvaris will post -3.15 earnings per share for the current fiscal year.

Insider Activity at Pharvaris

In related news, CEO Berndt Modig sold 2,292 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $34.77, for a total transaction of $79,692.84. Following the transaction, the chief executive officer directly owned 130,625 shares of the company’s stock, valued at approximately $4,541,831.25. This represents a 1.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Anne Lesage sold 30,703 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total value of $1,089,649.47. Following the completion of the sale, the insider directly owned 93,969 shares of the company’s stock, valued at $3,334,959.81. This trade represents a 24.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 118,655 shares of company stock valued at $4,188,002 in the last three months. Corporate insiders own 11.84% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in PHVS. venBio Partners LLC acquired a new position in Pharvaris during the 2nd quarter valued at about $160,569,809. Wellington Management Group LLP bought a new position in Pharvaris during the 3rd quarter valued at $43,282,000. 5AM Venture Management LLC purchased a new position in Pharvaris during the 2nd quarter worth $27,581,008. California State Teachers Retirement System boosted its holdings in Pharvaris by 3,210.1% during the 2nd quarter. California State Teachers Retirement System now owns 799,490 shares of the company’s stock worth $27,646,000 after acquiring an additional 775,337 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP grew its stake in shares of Pharvaris by 72.7% in the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock worth $45,796,000 after acquiring an additional 772,583 shares in the last quarter.

Key Headlines Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Positive Phase 3 CHAPTER-3 results: Deucrictibant XR met the primary endpoint and all secondary efficacy endpoints with statistical significance in the pivotal study, demonstrating a reduction in HAE attacks. Pharvaris plans to use the results to support marketing-authorization applications beginning in the first half of 2027. Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study
• Positive Sentiment: Late-stage drug validation: Reports characterized the experimental oral therapy as meeting the main goal of the trial, a potentially important advantage in HAE, where patients may value an oral preventive option. The results helped drive the stock higher and strengthened expectations for Pharvaris’ pipeline. Pharvaris’ genetic disorder drug meets main goal in late-stage trial
• Positive Sentiment: Analyst support increased: HC Wainwright reaffirmed a “buy” rating and set a $60 price target, while Wedbush maintained an “outperform” rating with a $42 target. A separate report placed the analyst consensus target at $51.08, indicating continued upside expectations if the program advances successfully. Analysts Set Pharvaris Price Target at $51.08
• Neutral Sentiment: The topline results are encouraging but additional regulatory review, application submissions, and potential approval remain ahead. Pharvaris is also a loss-making clinical-stage company, so valuation will remain sensitive to development, regulatory, and commercialization risks.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.